Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb reported Q2 revenue of $12.9 billion, up 6% year over year, while EPS rose 153% to $1.62 and free cash flow exceeded $3 billion. The stock is up more than 17% year to date but trades below 10x forward earnings; its growth portfolio generated nearly 60% of revenue and grew 15% in Q2, supporting the thesis that it can mitigate upcoming Eliquis and Opdivo patent expirations. The company also raised its quarterly dividend 1.6% to $0.63 per share, yielding 3.95%, maintains a $5 billion repurchase authorization, and has reportedly held merger discussions with AstraZeneca at a stated $400 billion valuation, though regulatory scrutiny would be substantial.

Analysis

BMY's discount is not a simple valuation anomaly: the market is assigning a low terminal value to the post-loss-of-exclusivity portfolio and discounting management's ability to replace high-margin legacy sales without further balance-sheet-intensive dealmaking. The key equity debate over the next 1-3 quarters is therefore not another earnings beat, but whether growth-brand sales accelerate enough to support durable earnings estimates after legacy-drug erosion. A sustained upgrade cycle would drive multiple expansion; mere in-line execution likely leaves the stock range-bound because the patent-cliff duration remains the dominant valuation input.

Capital returns provide downside support but do not eliminate the risk that free cash flow is redirected to debt reduction, pipeline acquisitions, or trial spending. The purported AZN angle should be treated as unmonetizable optionality rather than a base-case catalyst: a transaction of this scale would face financing, antitrust, and political obstacles, while AZN shareholders would likely demand a compelling strategic rationale. Any takeover-premium rally without a formal process is a potential short-term fade.

Contrarian view: the cleaner expression may be long BMY versus short a higher-multiple large-cap pharma rather than outright long. If BMY demonstrates that newer franchises can offset erosion, its rerating potential is meaningful precisely because expectations are low; however, failure of late-stage cardiovascular or oncology assets would remove the narrative that the pipeline can bridge the revenue gap and expose the stock to a value-trap multiple.

Key Decisions for Investors

• Initiate a 6-12 month long BMY / short ABBV pair in equal dollar amounts only after the next product-sales disclosure confirms growth-franchise momentum; target 10-15% relative upside from BMY multiple normalization, with exit if BMY cuts forward earnings or free-cash-flow guidance.
• For outright exposure, prefer a 9-12 month BMY call spread rather than stock: buy near-ATM calls and sell 15-20% OTM calls to isolate rerating/M&A optionality while limiting patent-cliff downside. Do not pay elevated implied volatility solely for takeover speculation.
• Treat reported AZN interest as an event-monitoring item, not a trade. Add a price alert for an unexplained BMY move above 10% on renewed deal reports; absent a named financing structure or regulatory pathway, consider trimming long exposure into that strength.
• Monitor quarterly net sales for the growth portfolio, revised 2027-2028 revenue guidance, and net-debt trajectory. Two consecutive quarters of decelerating growth-brand sales or a material pipeline setback falsifies the rerating thesis and argues for closing the pair.